IMAB - I-Mab on go with Phase 2 trial of enoblituzumab + pembrolizumab in China in solid tumors

I-Mab (NASDAQ:IMAB) announces that the Center for Drug Evaluation (NYSE:CDE) of China has approved its Investigational New Drug (IND) submission for the initiation of a phase 2 trial in China for enoblituzumab (also known as TJ271) in combination with pembrolizumab (Keytruda) in patients with solid tumors, including non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), and other selected cancers. I-Mab has acquired exclusive rights to develop and commercialize enoblituzumab in Greater China from MacroGenics (NASDAQ:MGNX). The trial is designed as a "basket" clinical trial in patients with NSCLC, UC, and other selected cancer types based on previous studies conducted by MGNX. These previous studies have indicated that combination therapy resulted in anti-tumor activity in recurrent or metastatic NSCLC and squamous cell carcinoma of the head and neck.

For further details see:

I-Mab on go with Phase 2 trial of enoblituzumab + pembrolizumab in China in solid tumors